The global Rivaroxaban market was valued at 7198.87 Million USD in 2020 and will grow with a CAGR of 8.61% from 2020 to 2027, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8-12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.The global average price of Rivaroxaban is in the decreasing trend, from 5.62 USD/Unit in 2011 to 5.34 USD/Unit in 2015. With the situation of global economy, prices will be in slowly decreasing trend in the following five years.
By Market Verdors:
Bayer
J&J
By Types:
2.5 mg
10 mg
15 mg
20 mg
By Applications:
Acute Coronary Syndrome (ACS)
Venous Thromboembolism (VTE)
Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market's competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2022-2027)
1.4.2 East Asia Market States and Outlook (2022-2027)
1.4.3 Europe Market States and Outlook (2022-2027)
1.4.4 South Asia Market States and Outlook (2022-2027)
1.4.5 Southeast Asia Market States and Outlook (2022-2027)
1.4.6 Middle East Market States and Outlook (2022-2027)
1.4.7 Africa Market States and Outlook (2022-2027)
1.4.8 Oceania Market States and Outlook (2022-2027)
1.4.9 South America Market States and Outlook (2022-2027)
1.5 Global Rivaroxaban Market Size Analysis from 2022 to 2027
1.5.1 Global Rivaroxaban Market Size Analysis from 2022 to 2027 by Consumption Volume
1.5.2 Global Rivaroxaban Market Size Analysis from 2022 to 2027 by Value
1.5.3 Global Rivaroxaban Price Trends Analysis from 2022 to 2027
1.6 COVID-19 Outbreak: Rivaroxaban Industry Impact
Chapter 2 Global Rivaroxaban Competition by Types, Applications, and Top Regions and Countries
2.1 Global Rivaroxaban (Volume and Value) by Type
2.1.1 Global Rivaroxaban Consumption and Market Share by Type (2016-2021)
2.1.2 Global Rivaroxaban Revenue and Market Share by Type (2016-2021)
2.2 Global Rivaroxaban (Volume and Value) by Application
2.2.1 Global Rivaroxaban Consumption and Market Share by Application (2016-2021)
2.2.2 Global Rivaroxaban Revenue and Market Share by Application (2016-2021)
2.3 Global Rivaroxaban (Volume and Value) by Regions
2.3.1 Global Rivaroxaban Consumption and Market Share by Regions (2016-2021)
2.3.2 Global Rivaroxaban Revenue and Market Share by Regions (2016-2021)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2016-2021 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2016-2021 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Rivaroxaban Sales, Consumption, Export, Import by Regions (2016-2021)
4.1 Global Rivaroxaban Consumption by Regions (2016-2021)
4.2 North America Rivaroxaban Sales, Consumption, Export, Import (2016-2021)
4.3 East Asia Rivaroxaban Sales, Consumption, Export, Import (2016-2021)
4.4 Europe Rivaroxaban Sales, Consumption, Export, Import (2016-2021)
4.5 South Asia Rivaroxaban Sales, Consumption, Export, Import (2016-2021)
4.6 Southeast Asia Rivaroxaban Sales, Consumption, Export, Import (2016-2021)
4.7 Middle East Rivaroxaban Sales, Consumption, Export, Import (2016-2021)
4.8 Africa Rivaroxaban Sales, Consumption, Export, Import (2016-2021)
4.9 Oceania Rivaroxaban Sales, Consumption, Export, Import (2016-2021)
4.10 South America Rivaroxaban Sales, Consumption, Export, Import (2016-2021)
Chapter 5 North America Rivaroxaban Market Analysis
5.1 North America Rivaroxaban Consumption and Value Analysis
5.1.1 North America Rivaroxaban Market Under COVID-19
5.2 North America Rivaroxaban Consumption Volume by Types
5.3 North America Rivaroxaban Consumption Structure by Application
5.4 North America Rivaroxaban Consumption by Top Countries
5.4.1 United States Rivaroxaban Consumption Volume from 2016 to 2021
5.4.2 Canada Rivaroxaban Consumption Volume from 2016 to 2021
5.4.3 Mexico Rivaroxaban Consumption Volume from 2016 to 2021
Chapter 6 East Asia Rivaroxaban Market Analysis
6.1 East Asia Rivaroxaban Consumption and Value Analysis
6.1.1 East Asia Rivaroxaban Market Under COVID-19
6.2 East Asia Rivaroxaban Consumption Volume by Types
6.3 East Asia Rivaroxaban Consumption Structure by Application
6.4 East Asia Rivaroxaban Consumption by Top Countries
6.4.1 China Rivaroxaban Consumption Volume from 2016 to 2021
6.4.2 Japan Rivaroxaban Consumption Volume from 2016 to 2021
6.4.3 South Korea Rivaroxaban Consumption Volume from 2016 to 2021
Chapter 7 Europe Rivaroxaban Market Analysis
7.1 Europe Rivaroxaban Consumption and Value Analysis
7.1.1 Europe Rivaroxaban Market Under COVID-19
7.2 Europe Rivaroxaban Consumption Volume by Types
7.3 Europe Rivaroxaban Consumption Structure by Application
7.4 Europe Rivaroxaban Consumption by Top Countries
7.4.1 Germany Rivaroxaban Consumption Volume from 2016 to 2021
7.4.2 UK Rivaroxaban Consumption Volume from 2016 to 2021
7.4.3 France Rivaroxaban Consumption Volume from 2016 to 2021
7.4.4 Italy Rivaroxaban Consumption Volume from 2016 to 2021
7.4.5 Russia Rivaroxaban Consumption Volume from 2016 to 2021
7.4.6 Spain Rivaroxaban Consumption Volume from 2016 to 2021
7.4.7 Netherlands Rivaroxaban Consumption Volume from 2016 to 2021
7.4.8 Switzerland Rivaroxaban Consumption Volume from 2016 to 2021
7.4.9 Poland Rivaroxaban Consumption Volume from 2016 to 2021
Chapter 8 South Asia Rivaroxaban Market Analysis
8.1 South Asia Rivaroxaban Consumption and Value Analysis
8.1.1 South Asia Rivaroxaban Market Under COVID-19
8.2 South Asia Rivaroxaban Consumption Volume by Types
8.3 South Asia Rivaroxaban Consumption Structure by Application
8.4 South Asia Rivaroxaban Consumption by Top Countries
8.4.1 India Rivaroxaban Consumption Volume from 2016 to 2021
8.4.2 Pakistan Rivaroxaban Consumption Volume from 2016 to 2021
8.4.3 Bangladesh Rivaroxaban Consumption Volume from 2016 to 2021
Chapter 9 Southeast Asia Rivaroxaban Market Analysis
9.1 Southeast Asia Rivaroxaban Consumption and Value Analysis
9.1.1 Southeast Asia Rivaroxaban Market Under COVID-19
9.2 Southeast Asia Rivaroxaban Consumption Volume by Types
9.3 Southeast Asia Rivaroxaban Consumption Structure by Application
9.4 Southeast Asia Rivaroxaban Consumption by Top Countries
9.4.1 Indonesia Rivaroxaban Consumption Volume from 2016 to 2021
9.4.2 Thailand Rivaroxaban Consumption Volume from 2016 to 2021
9.4.3 Singapore Rivaroxaban Consumption Volume from 2016 to 2021
9.4.4 Malaysia Rivaroxaban Consumption Volume from 2016 to 2021
9.4.5 Philippines Rivaroxaban Consumption Volume from 2016 to 2021
9.4.6 Vietnam Rivaroxaban Consumption Volume from 2016 to 2021
9.4.7 Myanmar Rivaroxaban Consumption Volume from 2016 to 2021
Chapter 10 Middle East Rivaroxaban Market Analysis
10.1 Middle East Rivaroxaban Consumption and Value Analysis
10.1.1 Middle East Rivaroxaban Market Under COVID-19
10.2 Middle East Rivaroxaban Consumption Volume by Types
10.3 Middle East Rivaroxaban Consumption Structure by Application
10.4 Middle East Rivaroxaban Consumption by Top Countries
10.4.1 Turkey Rivaroxaban Consumption Volume from 2016 to 2021
10.4.2 Saudi Arabia Rivaroxaban Consumption Volume from 2016 to 2021
10.4.3 Iran Rivaroxaban Consumption Volume from 2016 to 2021
10.4.4 United Arab Emirates Rivaroxaban Consumption Volume from 2016 to 2021
10.4.5 Israel Rivaroxaban Consumption Volume from 2016 to 2021
10.4.6 Iraq Rivaroxaban Consumption Volume from 2016 to 2021
10.4.7 Qatar Rivaroxaban Consumption Volume from 2016 to 2021
10.4.8 Kuwait Rivaroxaban Consumption Volume from 2016 to 2021
10.4.9 Oman Rivaroxaban Consumption Volume from 2016 to 2021
Chapter 11 Africa Rivaroxaban Market Analysis
11.1 Africa Rivaroxaban Consumption and Value Analysis
11.1.1 Africa Rivaroxaban Market Under COVID-19
11.2 Africa Rivaroxaban Consumption Volume by Types
11.3 Africa Rivaroxaban Consumption Structure by Application
11.4 Africa Rivaroxaban Consumption by Top Countries
11.4.1 Nigeria Rivaroxaban Consumption Volume from 2016 to 2021
11.4.2 South Africa Rivaroxaban Consumption Volume from 2016 to 2021
11.4.3 Egypt Rivaroxaban Consumption Volume from 2016 to 2021
11.4.4 Algeria Rivaroxaban Consumption Volume from 2016 to 2021
11.4.5 Morocco Rivaroxaban Consumption Volume from 2016 to 2021
Chapter 12 Oceania Rivaroxaban Market Analysis
12.1 Oceania Rivaroxaban Consumption and Value Analysis
12.2 Oceania Rivaroxaban Consumption Volume by Types
12.3 Oceania Rivaroxaban Consumption Structure by Application
12.4 Oceania Rivaroxaban Consumption by Top Countries
12.4.1 Australia Rivaroxaban Consumption Volume from 2016 to 2021
12.4.2 New Zealand Rivaroxaban Consumption Volume from 2016 to 2021
Chapter 13 South America Rivaroxaban Market Analysis
13.1 South America Rivaroxaban Consumption and Value Analysis
13.1.1 South America Rivaroxaban Market Under COVID-19
13.2 South America Rivaroxaban Consumption Volume by Types
13.3 South America Rivaroxaban Consumption Structure by Application
13.4 South America Rivaroxaban Consumption Volume by Major Countries
13.4.1 Brazil Rivaroxaban Consumption Volume from 2016 to 2021
13.4.2 Argentina Rivaroxaban Consumption Volume from 2016 to 2021
13.4.3 Columbia Rivaroxaban Consumption Volume from 2016 to 2021
13.4.4 Chile Rivaroxaban Consumption Volume from 2016 to 2021
13.4.5 Venezuela Rivaroxaban Consumption Volume from 2016 to 2021
13.4.6 Peru Rivaroxaban Consumption Volume from 2016 to 2021
13.4.7 Puerto Rico Rivaroxaban Consumption Volume from 2016 to 2021
13.4.8 Ecuador Rivaroxaban Consumption Volume from 2016 to 2021
Chapter 14 Company Profiles and Key Figures in Rivaroxaban Business
14.1 Bayer
14.1.1 Bayer Company Profile
14.1.2 Bayer Rivaroxaban Product Specification
14.1.3 Bayer Rivaroxaban Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.2 J&J
14.2.1 J&J Company Profile
14.2.2 J&J Rivaroxaban Product Specification
14.2.3 J&J Rivaroxaban Production Capacity, Revenue, Price and Gross Margin (2016-2021)
Chapter 15 Global Rivaroxaban Market Forecast (2022-2027)
15.1 Global Rivaroxaban Consumption Volume, Revenue and Price Forecast (2022-2027)
15.1.1 Global Rivaroxaban Consumption Volume and Growth Rate Forecast (2022-2027)
15.1.2 Global Rivaroxaban Value and Growth Rate Forecast (2022-2027)
15.2 Global Rivaroxaban Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027)
15.2.1 Global Rivaroxaban Consumption Volume and Growth Rate Forecast by Regions (2022-2027)
15.2.2 Global Rivaroxaban Value and Growth Rate Forecast by Regions (2022-2027)
15.2.3 North America Rivaroxaban Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.4 East Asia Rivaroxaban Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.5 Europe Rivaroxaban Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.6 South Asia Rivaroxaban Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.7 Southeast Asia Rivaroxaban Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.8 Middle East Rivaroxaban Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.9 Africa Rivaroxaban Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.10 Oceania Rivaroxaban Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.11 South America Rivaroxaban Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.3 Global Rivaroxaban Consumption Volume, Revenue and Price Forecast by Type (2022-2027)
15.3.1 Global Rivaroxaban Consumption Forecast by Type (2022-2027)
15.3.2 Global Rivaroxaban Revenue Forecast by Type (2022-2027)
15.3.3 Global Rivaroxaban Price Forecast by Type (2022-2027)
15.4 Global Rivaroxaban Consumption Volume Forecast by Application (2022-2027)
15.5 Rivaroxaban Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
The global Rivaroxaban market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field ev...
Overview of the Global Rivaroxaban Market:The report discusses everything a marketer requires before investing in the global Rivaroxaban Market during the forecast period 2022-2029. It provides detailed insight into current trends, market shares, market size, and sales val...
The global Rivaroxaban market was valued at 7198.87 Million USD in 2020 and will grow with a CAGR of 8.61% from 2020 to 2027, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in ...
The research team projects that the Rivaroxaban market size will grow from XXX in 2020 to XXX by 2027, at an estimated CAGR of XX. The base year considered for the study is 2020, and the market size is projected from 2020 to 2027.
The prime objective of this report is to help the user under...
The global market size of Investigation Rivaroxaban is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024.
Global Investigation Rivaroxaban Market Report 2019 - Market Size, Share, Price, Tr...
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut an...